CoChat

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

Open access

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Abstract

Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors (including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both opened new avenues for cancer treatment, but the clinical potential of combined disruption of inhibitory checkpoints and CAR T cell therapy remains incompletely explored. Here we show that programmed death ligand 1 (PD-L1) expression on tumor cells can render human CAR T cells (anti-CD19 4-1BBζ) hypo-functional, resulting in impaired tumor clearance in a sub-cutaneous xenograft model. To overcome this suppressed anti-tumor response, we developed a protocol for combined Cas9 ribonucleoprotein (Cas9 RNP)-mediated gene editing and lentiviral transduction to generate PD-1 deficient anti-CD19 CAR T cells. Pdcd1 (PD-1) disruption augmented CAR T cell mediated killing of tumor cells in vitro and enhanced clearance of PD-L1+ tumor xenografts in vivo. This study demonstrates improved therapeutic efficacy of Cas9-edited CAR T cells and highlights the potential of precision genome engineering to enhance next-generation cell therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-00462-8

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PD-L1 expression in human K562 myelogenous leukemia cells inhibits anti-CD19 CAR T cell function in vitro and tumor clearance in vivo. (a) Schematic representation of CAR T cell interaction with either CD19+ or CD19+ PD-L1 K562 tumor cells. (b) CD8+ anti-CD19 CAR T cells exhibit reduced degranulation (CD107a staining) upon re-stimulation with CD19+ PD-L1+ K562 cells. Representative CD107a staining is shown, gated on CD8+ CAR+ T cells. Normalized CD107a staining shows ~15% reduction in degranulation upon co-culture with CD19+ PD-L1+ targets over three independent experiments (**p = 0.009, Student’s t-test). (c) CD19+ PD-L1+ K562 cells are resistant to anti-CD19 CAR-mediated lysis in an in vitro killing assay. Left panel: a complete effector:target ratio titration is shown for a representative experiment. Mean ± S.D. for triplicate wells in a single experiment are plotted. Right panel (bar chart): CD19+ PD-L1+ K562 cells induce ~40% reduction in specific lysis relative to CD19+ K562 cells at effector:target ratio of 2:1 (*p = 0.042, Student’s t-test). The experiment was performed three times; error bars are S.D. (d) Experimental design for subcutaneous xenograft model. (e) CD19+ PD-L1+ subcutaneous xenografts impair anti-CD19 CAR mediated tumor clearance. NOD-scid-IL-2Rγ−/− (NSG) mice were injected with 5 × 106 CD19+ or CD19+ PD-L1+ K562 cells subcutaneously. Mice with established tumors (100–250 mm3) were injected intravenously with 2 × 106 CD4+ and 2 × 106 CD8+ anti-CD19 CAR T cells and tumor burden measured longitudinally by caliper. Shown are tumor burdens for individual mice (n = 5 per tumor type). (f) Kaplan-Meier curve for experiment described in Fig. 1E. A statistically significant difference in survival was observed between animals bearing CD19+ vs. CD19+ PD-L1+ tumors (*p = 0.016, Gehan-Breslow-Wilcoxon test).
Figure 1 PD-L1 expression in human K562 myelogenous leukemia cells inhibits anti-CD19 CAR T cell function in vitro and tumor clearance in vivo. (a) Schematic representation of CAR T cell interaction with either CD19+ or CD19+ PD-L1 K562 tumor cells. (b) CD8+ anti-CD19 CAR T cells exhibit reduced degranulation (CD107a staining) upon re-stimulation with CD19+ PD-L1+ K562 cells. Representative CD107a staining is shown, gated on CD8+ CAR+ T cells. Normalized CD107a staining shows ~15% reduction in degranulation upon co-culture with CD19+ PD-L1+ targets over three independent experiments (**p = 0.009, Student’s t-test). (c) CD19+ PD-L1+ K562 cells are resistant to anti-CD19 CAR-mediated lysis in an in vitro killing assay. Left panel: a complete effector:target ratio titration is shown for a representative experiment. Mean ± S.D. for triplicate wells in a single experiment are plotted. Right panel (bar chart): CD19+ PD-L1+ K562 cells induce ~40% reduction in specific lysis relative to CD19+ K562 cells at effector:target ratio of 2:1 (*p = 0.042, Student’s t-test). The experiment was performed three times; error bars are S.D. (d) Experimental design for subcutaneous xenograft model. (e) CD19+ PD-L1+ subcutaneous xenografts impair anti-CD19 CAR mediated tumor clearance. NOD-scid-IL-2Rγ−/− (NSG) mice were injected with 5 × 106 CD19+ or CD19+ PD-L1+ K562 cells subcutaneously. Mice with established tumors (100–250 mm3) were injected intravenously with 2 × 106 CD4+ and 2 × 106 CD8+ anti-CD19 CAR T cells and tumor burden measured longitudinally by caliper. Shown are tumor burdens for individual mice (n = 5 per tumor type). (f) Kaplan-Meier curve for experiment described in Fig. 1E. A statistically significant difference in survival was observed between animals bearing CD19+ vs. CD19+ PD-L1+ tumors (*p = 0.016, Gehan-Breslow-Wilcoxon test).CC BY · PubMed Central
Figure 2 Pdcd1 can be efficiently disrupted in CAR T cells using Cas9 ribonucleoproteins (Cas9 RNPs). (a) Schematic of protocol for combined CRISPR gene editing and lentiviral transduction of human primary T cells. (b) Efficient PD-1 deletion and CAR transduction in primary human T cells. PD-1 surface staining and CAR transduction were assessed 48 hours post editing. A >50% reduction in PD-1+ cells was routinely observed, with CAR transduction >70%. Right panel, individual dots represent independent editing experiments. (c) PD-1 edited CAR T cells are stable in culture. Resting PD-1 edited CD8+ anti-CD19 CAR T cells were re-stimulated with CD19+ K562 cells. Activation was measured by CD69 induction and percent reduction in PD-1+ cells measured by flow cytometry based on surface PD-1 expression; percent reduction of PD-1+ cells was similar to that observed 48 hours after editing (rightmost panel, pairwise plot).
Figure 2 Pdcd1 can be efficiently disrupted in CAR T cells using Cas9 ribonucleoproteins (Cas9 RNPs). (a) Schematic of protocol for combined CRISPR gene editing and lentiviral transduction of human primary T cells. (b) Efficient PD-1 deletion and CAR transduction in primary human T cells. PD-1 surface staining and CAR transduction were assessed 48 hours post editing. A >50% reduction in PD-1+ cells was routinely observed, with CAR transduction >70%. Right panel, individual dots represent independent editing experiments. (c) PD-1 edited CAR T cells are stable in culture. Resting PD-1 edited CD8+ anti-CD19 CAR T cells were re-stimulated with CD19+ K562 cells. Activation was measured by CD69 induction and percent reduction in PD-1+ cells measured by flow cytometry based on surface PD-1 expression; percent reduction of PD-1+ cells was similar to that observed 48 hours after editing (rightmost panel, pairwise plot).CC BY · PubMed Central
Figure 3 CRISPR-mediated PD-1 editing rescues anti-CD19 CAR T cell function in vitro and enhances tumor clearance in vivo. (a) Diagram of PD-1 edited CAR T cell: K562 interactions (b) PD-1 edited CD8+ anti-CD19 CAR T cells (ΔPD-1) exhibit greater degranulation (CD107a staining) upon co-culture with CD19+ PD-L1+ K562 cells as compared to control CD8+ CAR T cells (*p = 0.018, Student’s t-test). (c) PD-1 edited CAR T cells are partially resistant to CD19+ PD-L1+ mediated inhibition of cytolysis. Left panel: percent lysis for control and PD-1 edited CD8+ anti-CD19 CAR T cells is shown across a range of effector:target ratios. Error bars are S.D. of triplicate wells in a single experiment. Right panel: normalized killing shows reduced PD-L1 dependent inhibition of killing in PD-1 edited CD8+ CAR T cells at effector:target ratio of 2:1 (*p = 0.03, paired t-test). The experiment was performed three independent times. (d) PD-1 deficient anti-CD19 CAR T cells exhibit enhanced anti-tumor efficacy and clear subcutaneous CD19+ PD-L1+ tumor xenografts. NSG mice were injected with 5 × 106 CD19+ PD-L1+ K562 cells subcutaneously. Mice with established tumors (100–250 mm3) were injected intravenously with 4 × 106 CD4+ CAR+ and 4 × 106 CD8+ CAR+ control T cells or PD-1 edited cells, and tumor burden measured longitudinally by caliper. Tumor burdens are mean ± SEM for each group (n = 6 mice per group). A statistically significant decrease in tumor burden of mice receiving PD-1 edited CAR T cells was observed at multiple points (*p < 0.05, **p < 0.01, Student’s t-test).
Figure 3 CRISPR-mediated PD-1 editing rescues anti-CD19 CAR T cell function in vitro and enhances tumor clearance in vivo. (a) Diagram of PD-1 edited CAR T cell: K562 interactions (b) PD-1 edited CD8+ anti-CD19 CAR T cells (ΔPD-1) exhibit greater degranulation (CD107a staining) upon co-culture with CD19+ PD-L1+ K562 cells as compared to control CD8+ CAR T cells (*p = 0.018, Student’s t-test). (c) PD-1 edited CAR T cells are partially resistant to CD19+ PD-L1+ mediated inhibition of cytolysis. Left panel: percent lysis for control and PD-1 edited CD8+ anti-CD19 CAR T cells is shown across a range of effector:target ratios. Error bars are S.D. of triplicate wells in a single experiment. Right panel: normalized killing shows reduced PD-L1 dependent inhibition of killing in PD-1 edited CD8+ CAR T cells at effector:target ratio of 2:1 (*p = 0.03, paired t-test). The experiment was performed three independent times. (d) PD-1 deficient anti-CD19 CAR T cells exhibit enhanced anti-tumor efficacy and clear subcutaneous CD19+ PD-L1+ tumor xenografts. NSG mice were injected with 5 × 106 CD19+ PD-L1+ K562 cells subcutaneously. Mice with established tumors (100–250 mm3) were injected intravenously with 4 × 106 CD4+ CAR+ and 4 × 106 CD8+ CAR+ control T cells or PD-1 edited cells, and tumor burden measured longitudinally by caliper. Tumor burdens are mean ± SEM for each group (n = 6 mice per group). A statistically significant decrease in tumor burden of mice receiving PD-1 edited CAR T cells was observed at multiple points (*p < 0.05, **p < 0.01, Student’s t-test).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 757

Metadata

Authors
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A.
Affiliations
  • Howard Hughes Medical Institute (US)
  • University of California, San Francisco (US)
Corresponding author
Lim, Wendell A.
Venue
Scientific Reports
Published
2017-04-07
Volume
7
Issue
1
Pages
737-737
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2604982880
Cited by
757
References
39
Citations by year
2026: 58 · 2025: 72 · 2024: 70 · 2023: 72 · 2022: 94 · 2021: 107 · 2020: 122 · 2019: 85 · 2018: 67 · 2017: 10
FWCI
34.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • KOPS (University of Konstanz) (submittedVersion, cc-by)
Funders
  • Howard Hughes Medical Institute (R01 CA196277)
  • Burroughs Wellcome Fund
  • Deutsche Forschungsgemeinschaft
  • National Institutes of Health (EY016546)
  • University of California, San Francisco
  • National Eye Institute (PN2EY016546)
  • National Cancer Institute (R01CA196277)
  • National Institute of General Medical Sciences (T32GM067547, R01GM055040)
  • National Institute of Allergy and Infectious Diseases (F32AI120352)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords
CRISPR/Cas9 genome editing, PD-1, PD-L1, chimeric antigen receptor T cells, CD19 CAR T cells, 4-1BB, lentiviral transduction, Cas9 ribonucleoprotein, cancer immunotherapy, antitumor efficacy, anti-PD-1 therapy
MeSH terms
Animals, Antigens, Neoplasm, Female, Humans, Neoplasms, Receptors, Antigen, T-Cell, T-Lymphocytes, Biomarkers, Gene Expression, Immunophenotyping, Mice, Knockout, Gene Targeting, Antigens, CD19, Cell Line, Tumor, Mice, Gene Knockdown Techniques, B7-H1 Antigen, Programmed Cell Death 1 Receptor, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. https://app.cochat.ai/papers/10.1038/s41598-017-00462-8
The paper
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017). CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Scientific Reports. https://doi.org/10.1038/s41598-017-00462-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.